A Review of Basal-Bolus Therapy Using Insulin Glargine and Insulin Lispro in the Management of Diabetes Mellitus

Basal-bolus therapy (BBT) refers to the combination of a long-acting basal insulin with a rapid-acting insulin at mealtimes. Basal insulin glargine 100 U/mL and prandial insulin lispro have been available for many years and there is a substantial evidence base to support the efficacy and safety of these agents when they are used in BBT or basal-plus therapy for patients with type 1 or type 2 diabetes mellitus (T1DM, T2DM). With the growing availability of alternative insulins for use in such regimens, it seems timely to review the data regarding BBT with insulin glargine 100 U/mL and insulin lispro. In patients with T1DM, BBT with insulin glargine plus insulin lispro provides similar or better glycemic control and leads to less nocturnal hypoglycemia compared to BBT using human insulin as the basal and/or prandial component, and generally provides similar glycemic control and rates of severe hypoglycemia to those achieved with insulin lispro administered by continuous subcutaneous insulin infusion (CSII). Studies evaluating BBT with insulin glargine plus insulin lispro in patients with T2DM also demonstrate the efficacy and safety of these insulins. Available data suggest that BBT with insulin glargine and insulin lispro provides similar levels of efficacy and safety in pediatric and adult populations with T1DM and in adult patients and those aged more than 65 years with T2DM. These insulin preparations also appear to be safe and effective for controlling T2DM in people of different ethnicities and in patients with T1DM or T2DM and comorbidities.FundingEli Lilly and Company.

• Publication year

  2018

• Venue

  Diabetes Therapy

• Publication date

  2018-04-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s13300-018-0422-4PMID 29654514PMCID 5984925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Section 9: Pharmacologic Approaches to Glycemic Treatment

  2024cited by this paper
• Insulin analogues

  2019cited by this paper
• Insulin lispro

  2018cited by this paper
• Comparison of insulin intensification strategies with insulin lispro low mixture twice daily versus basal insulin glargine and prandial insulin lispro once daily in East Asian and Caucasian patients with type 2 diabetes mellitus

  2017cited by this paper
• Attributes Influencing Insulin Pen Preference Among Caregivers and Patients With Diabetes Who Require Greater Than 20 Units of Mealtime Insulin

  2016cited by this paper
• Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

  2016cited by this paper
• The past, present, and future of basal insulins

  2016cited by this paper
• Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus.

  2016cited by this paper
• Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus

  2016cited by this paper
• 8. Pharmacologic Approaches to Glycemic Treatment

  2016cited by this paper
• Comparison of efficacy and safety of two starting insulin regimens in non-Asian, Asian Indian, and East Asian patients with type 2 diabetes: a post hoc analysis of the PARADIGM study

  2016cited by this paper
• Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.

  2016influential reference
• CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY.

  2016influential reference
• Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.

  2015cited by this paper
• Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin‐naïve or previously treated with insulin glargine: a randomized, double‐blind controlled trial (the ELEMENT 2 study)

  2015cited by this paper
• GLP-1 RAs as compared to prandial insulin after failure of basal insulin in type 2 diabetes: lessons from the 4B and Get-Goal DUO 2 trials.

  2015cited by this paper
• Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, con

  2015influential reference
• Insulin lispro low mixture twice daily vs basal insulin glargine once daily and prandial insulin lispro once daily as insulin intensification strategies in patients with type 2 diabetes: Latin American subpopulation analysis of a randomized trial

  2015cited by this paper
• Bioequivalence and comparative pharmacodynamics of insulin lispro 200 U/mL relative to insulin lispro (Humalog®) 100 U/mL

  2015cited by this paper
• Efficacy and safety of LY2963016 insulin glargine compared with insulin glargine (Lantus®) in patients with type 1 diabetes in a randomized controlled trial: the ELEMENT 1 study

  2015cited by this paper
• Basal insulin intensification in type 2 diabetes: a key role for GLP-1 receptor agonists.

  2015cited by this paper
• Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies

  2015cited by this paper
• A Comparison of Glide Force Characteristics Between 2 Prefilled Insulin Lispro Pens

  2015cited by this paper
• Evaluation of Glycemia Control Achieved by Glargine and Lispro Versus Detemir and Aspart Insulin Regimes in Type 2 Diabetics Undergoing Surgery

  2015cited by this paper
• Efficacy and Risk of Hypoglycemia With Use of Insulin Glargine or Comparators in Patients With Cardiovascular Risk Factors

  2014cited by this paper
• The Association of Basal Insulin Glargine and/or n-3 Fatty Acids With Incident Cancers in Patients With Dysglycemia

  2014cited by this paper
• Type 1 Diabetes Through the Life Span: A Position Statement of the American Diabetes Association

  2014influential reference
• Insulin therapy for type 2 diabetes mellitus.

  2014cited by this paper
• Evolution of insulin: from human to analog.

  2014cited by this paper
• Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial

  2014cited by this paper
• The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care

  2014cited by this paper
• AUTONOMY: The First Randomized Trial Comparing Two Patient-Driven Approaches to Initiate and Titrate Prandial Insulin Lispro in Type 2 Diabetes

  2014influential reference
• Initiation and Gradual Intensification of Premixed Insulin Lispro Therapy Versus Basal ± Mealtime Insulin in Patients With Type 2 Diabetes Eating Light Breakfasts

  2014cited by this paper
• Coronary artery disease The relationship between glycaemic variability and cardiovascular complications in patients with acute myocardial infarction and type 2 diabetes : a report from the DIGAMI 2 trial

  2013cited by this paper
• Is There Evidence to Support Use of Premixed or Prandial Insulin Regimens in Insulin-Naive or Previously Insulin-Treated Type 2 Diabetic Patients?

  2013cited by this paper
• Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events

  2013cited by this paper
• Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.

  2013cited by this paper
• Effect of Insulin Glargine and n-3 FA on Carotid Intima-Media Thickness in PeopleWithDysglycemiaatHighRiskfor Cardiovascular Events The Glucose Reduction and Atherosclerosis Continuing Evaluation Study ( ORIGIN-GRACE )

  2013cited by this paper
• Intensifying insulin therapy: what options are available to patients with type 2 diabetes?

  2013cited by this paper
• Insulin therapy in type 2 diabetes mellitus.

  2012cited by this paper
• Review of Insulin and its Analogues in Diabetes Mellitus

  2012cited by this paper
• Cardioprotective role of insulin: Advantage analogues

  2012cited by this paper
• Cumulative clinical experience with use of insulin lispro: critical appraisal, role in therapy, and patient considerations

  2012cited by this paper
• Insulin glargine improves glycemic control and quality of life in type 2 diabetic patients on hemodialysis.

  2012cited by this paper
• Meta-Analysis of Maternal and Neonatal Outcomes Associated with the Use of Insulin Glargine versus NPH Insulin during Pregnancy

  2012cited by this paper
• The pharmacokinetics and pharmacodynamics of rapid‐acting insulin analogues and their clinical consequences

  2012cited by this paper
• A study comparing insulin lispro mix 25 with glargine plus lispro therapy in patients with Type 2 diabetes who have inadequate glycaemic control on oral anti‐hyperglycaemic medication: results of the PARADIGM study

  2012cited by this paper
• Plasma Exposure to Insulin Glargine and Its Metabolites M1 and M2 After Subcutaneous Injection of Therapeutic and Supratherapeutic Doses of Glargine in Subjects With Type 1 Diabetes

  2012cited by this paper
• Insulins: past, present, and future.

  2012cited by this paper
• Basal Plus Basal–Bolus Approach in Type 2 Diabetes

  2011cited by this paper
• Insulin during pregnancy, labour and delivery.

  2011cited by this paper
• Letter Written in Response to van Bon et al.: “Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial”

  2011cited by this paper
• Insulin injections in relation to meals in the hospital medicine ward: comparison of 2 protocols.

  2011cited by this paper
• Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes

  2011cited by this paper
• Comparison of insulin lispro protamine suspension versus insulin glargine once daily in basal‐bolus therapies with insulin lispro in type 2 diabetes patients: a prospective randomized open‐label trial

  2011influential reference
• Insulin Glulisine Compared to Insulin Aspart and to Insulin Lispro Administered by Continuous Subcutaneous Insulin Infusion in Patients with Type 1 Diabetes: A Randomized Controlled Trial

  2011cited by this paper
• Rapid-acting insulin analogues in Basal-bolus regimens in type 1 diabetes mellitus.

  2010cited by this paper
• Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes

  2010cited by this paper
• Prandial–basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes

  2010cited by this paper
• Self-monitoring of blood glucose in type 2 diabetes: systematic review.

  2010cited by this paper
• Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

  2010cited by this paper
• Distinct pharmacodynamics of insulin glargine and insulin detemir: crossover comparison in Type 1 and Type 2 diabetic patients on basal-bolus regimen.

  2010cited by this paper
• Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine.

  2010cited by this paper
• Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers.

  2010cited by this paper
• In Vitro Metabolic and Mitogenic Signaling of Insulin Glargine and Its Metabolites

  2010cited by this paper
• Randomized, open-label, parallel-group evaluations of basal-bolus therapy versus insulin lispro premixed therapy in patients with type 2 diabetes mellitus failing to achieve control with starter insulin treatment and continuing oral antihyperglycemic drugs: a noninferiority intensification substudy

  2010cited by this paper
• Lower fasting blood glucose, glucose variability and nocturnal hypoglycaemia with glargine vs NPH basal insulin in subjects with Type 1 diabetes.

  2009cited by this paper
• Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

  2009cited by this paper
• Comparison of a Multiple Daily Insulin Injection Regimen (Basal Once-Daily Glargine Plus Mealtime Lispro) and Continuous Subcutaneous Insulin Infusion (Lispro) in Type 1 Diabetes

  2009cited by this paper
• Comparison of Glycemic Variability Associated With Insulin Glargine and Intermediate-Acting Insulin When Used as the Basal Component of Multiple Daily Injections for Adolescents With Type 1 Diabetes

  2009cited by this paper
• Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study

  2009cited by this paper
• Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.

  2009cited by this paper
• Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus

  2009cited by this paper
• Defining the role of basal and prandial insulin for optimal glycemic control.

  2009cited by this paper
• Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

  2009cited by this paper
• Comparison of a Multiple Daily Insulin Injection Regime (Basal Once-Daily Glargine plus Mealtime Lispro) and CSII (Lispro) in Type 1 Diabetes: a Randomized Open Parallel Multicenter Study

  2009cited by this paper
• Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.

  2008cited by this paper
• Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in people with Type 1 diabetes

  2008cited by this paper
• In Type 1 diabetic patients with good glycaemic control, blood glucose variability is lower during continuous subcutaneous insulin infusion than during multiple daily injections with insulin glargine

  2008influential reference
• Insulin glulisine, insulin lispro and regular human insulin show comparable end‐organ metabolic effects: an exploratory study

  2008cited by this paper
• Insulin glargine versus intermediate-acting insulin as the basal component of multiple daily injection regimens for adolescents with type 1 diabetes mellitus.

  2008cited by this paper
• Early retinopathy progression in four randomized trials comparing insulin glargine and Nph insulin

  2007cited by this paper
• Advancing Insulin Therapy in Type 2 Diabetes Previously Treated With Glargine Plus Oral Agents

  2007cited by this paper
• Insulin glulisine: a faster onset of action compared with insulin lispro

  2007cited by this paper
• Insulin glargine and receptor‐mediated signalling: clinical implications in treating type 2 diabetes

  2007cited by this paper
• Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin.

  2007cited by this paper
• Pancreatic extracts in the treatment of diabetes mellitus. 1922.

  2007cited by this paper
• Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross‐over trial in people with Type 1 diabetes

  2006cited by this paper
• Insulin analogues.

  2005cited by this paper
• Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes.

  2005cited by this paper
• CRYSTALLINE INSULIN*

  2005cited by this paper
• Flexible Insulin Therapy With Glargine Insulin Improved Glycemic Control and Reduced Severe Hypoglycemia Among Preschool-Aged Children With Type 1 Diabetes Mellitus

  2005cited by this paper
• Systemic allergy to human insulin and its rapid and long acting analogs: successful treatment by continuous subcutaneous insulin lispro infusion.

  2005cited by this paper
• Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

  2005cited by this paper
• Efficacy and safety of insulin glulisine in patients with type 1 diabetes.

  2005cited by this paper
• Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy

  2005influential reference
• A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes

  2005cited by this paper
• Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection with glargine as basal insulin: an open parallel long-term study.

  2004cited by this paper
• Better long‐term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal‐time lispro insulin

  2004cited by this paper
• Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.

  2003influential reference

• From guidelines to practice: an Egyptian expert opinion on type 2 diabetes mellitus management in primary care settings

  2025cites this paper
• Innovative approaches in insulin delivery: Exploring molecular techniques and system developments

  2025cites this paper
• Therapeutic Peptides in the Treatment of Digestive Inflammation: Current Advances and Future Prospects.

  2024cites this paper
• Type II Diabetes Mellitus And Anti-Diabetic Therapy Patterns In Hospital X, Central Java

  2024influential citation
• Trends in anti‐diabetic medication use, severe hyperglycaemia and severe hypoglycaemia among American Indian and Alaska Native Peoples, 2009–2013

  2024cites this paper
• Comprehensive Management of Diabetes Mellitus in the Elderly: A Review

  2023cites this paper
• Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions

  2022cites this paper
• Peptide Hormones in Medicine: A 100-Year History

  2022cites this paper
• Mechanical and Fluidic Analysis of Hollow Side-Open and Outer-Grooved Design of Microneedles

  2021cites this paper
• Cost comparisons of available brands of insulin glargine preparations

  2021cites this paper
• Comparison between Continuous Regular Insulin Infusion and Single Dose Subcutaneous Long Acting Insulin Injection in Intensive Care Unit

  2021cites this paper
• Iraqi Experts Consensus on the Management of Type 2 Diabetes/Prediabetes in Adults

  2020cites this paper
• African Cuisine-Centered Insulin Therapy: Expert Opinion on the Management of Hyperglycaemia in Adult Patients with Type 2 Diabetes Mellitus

  2020cites this paper
• Comparison of Analogue insulin with other insulins in patients with type 1 diabetes in Ahmedabad, Western India: A Rretrospective study.

  2020cites this paper
• Ultra rapid lispro improves postprandial glucose control compared with lispro in patients with type 1 diabetes: Results from the 26‐week PRONTO‐T1D study

  2020cites this paper
• Determination of amyloid core regions of insulin analogues fibrils

  2020cites this paper
• Development and Assessment of a Mobile Health Application for Monitoring the Linkage Among Treatment Factors of Type 1 Diabetes Mellitus

  2020cites this paper
• The Value of Follow-On Biopharma Innovation for Health Outcomes and Economic Growth

  year unknowncites this paper